Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.

Cellular signalling - 1 Jan 2017

Gonzalez N, Cardama G A, Comin M J, Segatori V I, Pifano M, Alonso D F, Gomez D E, Menna P L

Abstract excerpt

Tamoxifen is a standard endocrine therapy for estrogen receptor positive breast cancer patients. Despite its success, development of resistance mechanisms is still a serious clinical problem. Deregulation of survival signaling pathways play a key role in tamoxifen resistance, being upregulation of Rac1-PAK1 signaling pathway one of the most important. Here, we report the development of the breast cancer cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Estrogens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MCF-7 Cells

Share to p21-Activated Kinases

Share to Phosphoserine

Share to rac1 GTP-Binding Protein

Share to Tamoxifen

Share to Up-Regulation

Source

Identifiers

PMID: 27939839
DOI: 10.1016/j.cellsig.2016.12.002

Genes

PAK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells.PMID 27939839Read ↗

Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Semantic proximity Read ↗

A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancerSemantic proximity Read ↗

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.Semantic proximity Read ↗

Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast CancerSemantic proximity Read ↗

Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer.Semantic proximity Read ↗

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.Semantic proximity Read ↗

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.Semantic proximity Read ↗

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancerSemantic proximity Read ↗

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.Semantic proximity Read ↗

Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Semantic proximity Read ↗

β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells.Semantic proximity Read ↗

The PPARgamma antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARgamma-dependent and -independent mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.